Curiox Biosystems Co., Ltd

KOSDAQ:A445680 Stock Report

Market Cap: ₩301.2b

Curiox Biosystems Past Earnings Performance

Past criteria checks 0/6

Curiox Biosystems's earnings have been declining at an average annual rate of -5.6%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been declining at an average rate of 2.7% per year.

Key information

-5.6%

Earnings growth rate

22.7%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate-2.7%
Return on equity-27.1%
Net Margin-207.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?

Dec 16
Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?

We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn Rate

Jun 20
We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn Rate

We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To Grow

Mar 04
We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To Grow

Revenue & Expenses Breakdown

How Curiox Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A445680 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,967-12,37211,1322,360
30 Jun 245,697-10,90410,9312,223
31 Mar 246,224-10,66710,6122,310
31 Dec 236,788-10,04010,5922,109
30 Sep 237,113-11,59411,1882,460
31 Mar 238,612-9,95713,1011,834
31 Dec 227,237-11,49513,2191,470
31 Dec 215,523-14,52410,141460
31 Dec 204,384-6,2794,957172

Quality Earnings: A445680 is currently unprofitable.

Growing Profit Margin: A445680 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A445680 is unprofitable, and losses have increased over the past 5 years at a rate of 5.6% per year.

Accelerating Growth: Unable to compare A445680's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A445680 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (39.6%).


Return on Equity

High ROE: A445680 has a negative Return on Equity (-27.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 16:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Curiox Biosystems Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution